PRE-MARKET INDIAN STOCKS NEWS: Sun Pharmaceutical Industries (SUNP IN) agreed to extend most-favoured-nation drug pricing to US state Medicaid programmes

Happiest Minds Technologies (HAPPSTMN IN) - Co. signed definitive agreements to combine its business with ITC Infotech India. (Economic Times)

Kotak Mahindra Bank (KMB IN) - Co. has reportedly recommended executive directors Anup Saha and Paritosh Kashyap to the Reserve Bank of India as internal candidates to succeed CEO Ashok Vaswani when his term ends next year. (Moneycontrol)

Mankind Pharma (MANKIND IN) - Co. completed the transfer of its 100% stake in Broadway Hospitality Services to AKRK Projects LLP and its partners, following which Broadway ceased to be a wholly owned subsidiary. (Economic Times)

NCC (NJCC IN) - Co. received three orders worth a combined INR 4.30bln in August for its buildings division. (Moneycontrol)

NLC India (NLC IN) - Co.’s subsidiary NLC India Renewables incorporated a 51:49 joint venture with the Odisha Renewable Energy Development Agency named NIRL OREDA Renewables to develop green energy power plants. (Moneycontrol)

Sun Pharmaceutical Industries (SUNP IN) - Co. agreed to extend most-favoured-nation drug pricing to U.S. state Medicaid programmes and future innovative medicine launches in exchange for a two-year delay to impending U.S. tariffs. (Moneycontrol)

Welspun Corp (WLCO IN) - Co. will not proceed with the proposed sale of its 26% stake in Clean Max Dhyuthi to Welspun Living after the INR 76mln transaction was mutually cancelled, citing current demand, supply and power availability at the relevant location. (Economic Times)

Deals of this shape, pricing concessions traded against tariff relief, follow a pattern established by earlier agreements between large drugmakers and the US administration, in which most-favoured-nation commitments on Medicaid and new launches were exchanged for multi-year exemptions from threatened sectoral tariffs. The transmission channel for the stock is the removal of a tariff overhang on US-facing revenue, offset by margin compression on the Medicaid book and on future launches; Medicaid is typically a smaller share of an Indian generic manufacturer's US mix than the commercial channel, which is why the trade has tended to be received as net positive for the sector on prior occasions. The meaningful distinction is between companies that have signed and those still exposed to the tariff threat, and the peer read-across to other Indian pharma names with large US businesses has historically been immediate. What follows in these episodes is a queue of similar announcements, so further company confirmations and any detail on launch-pricing mechanics are the follow-ons. The remainder of the wrap is routine: order inflows, stake transfers and a bank succession process, with the Kotak CEO shortlist worth noting given the central bank's history of vetting internal candidates.